{"filing":{"accession_number":"0001689375-26-000052","cik":"0001689375","ticker":"TRDA","company_name":"Entrada Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"trda-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937526000052/trda-20260805.htm"},"events":[{"id":25212,"run_id":22876,"accession_number":"0001689375-26-000052","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 5, 2026. The disclosure includes condensed consolidated statements of operations showing collaboration revenue, operating expenses, net loss of $42.8 million, and balance sheet data with cash position of $223.0 million. The press release also provides clinical pipeline updates and forward-looking guidance on data readouts, which are typical components of a biotech earnings announcement.","company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25977,"accession_number":"0001689375-26-000052","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 5, 2026. The disclosure includes condensed consolidated statements of operations showing collaboration revenue, operating expenses, net loss of $42.8 million, and balance sheet data with cash position of $223.0 million. The press release also provides clinical pipeline updates and forward-looking guidance on data readouts, which are typical components of a biotech earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:19:37.175053+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25977,"accession_number":"0001689375-26-000052","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 5, 2026. The disclosure includes condensed consolidated statements of operations showing collaboration revenue, operating expenses, net loss of $42.8 million, and balance sheet data with cash position of $223.0 million. The press release also provides clinical pipeline updates and forward-looking guidance on data readouts, which are typical components of a biotech earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:19:37.175053+00:00","company_name":"Entrada Therapeutics, Inc.","ticker":"TRDA","filing_date":"2026-08-05"}]}